Table 2.
MCS patient’s antithrombotic therapy regiment adjustment based on TPM and or WBA results with one-week outcome.
| Sample # | Device | TEG CI | TEG MAAA (mm) | WBAAA (ohm) | Anticoagulant | INR | Aspirin | Aspirin Dose Change | Anticoagulant Dose Change | 1-Week Event |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 | HW | 1.2 | 34.0 | 2 | W | 1.9 | 81 qd | No | No | No |
| 13 | HW | 1.1 | 41.8 | 0 | W | 2.1 | 325 qd | No | No | No |
| 14 | HW | 0.5 | 13.2 | 2 | W | 2.4 | 162 qd | No | No | No |
| 15 | HMII | 1.7 | 40.2 | 2 | W | 4.1 | 81 qd | No | No | No |
| 16 | HW | −1.1 | 29.7 | 1 | W | 2.8 | 325 qd | No | No | No |
| 17 | HW | 2.0 | 36.3 | 0 | W | 1.9 | 81 qd | No | W dose > W | No |
| 18 | BiVAD | 0.0 | 21.1 | 0 | W | 1.8 | 325 qd | Discontinued | Discontinued | OHT |
| 19 | HMII | 1.9 | 33.6 | 0 | None | 1.4 | 162 qd | No | W added | No |
| 20 | HMII | −0.4 | 35.7 | 0 | W + UFH | 1.3 | 81 qd | No | No | No |
| 21 | HMII | −4.3 | 28.9 | 0 | UFH | 1.2 | 81 qd | No | No | No |
| 22 | LVAD | 1.5 | 49.3 | 0 | W | 2.6 | 325 qd | No | No | No |
| 23 | HMII | 2.0 | 69.6 | 20 | None | 1.9 | 81 qd | 325 qd | UFH added | No |
| 24 | HMII | −0.1 | 68.8 | 15 | W | 2.5 | 81 qd | No | No | No |
| 25 | HMII | 0.8 | 59.4 | 1 | W | 2.7 | 81 qd | No | W dose< | No |
| 26 | TAH | −3.5 | 22.6 | 3 | UFH | 1.8 | 81 qd | No | No | No |
| 27 | TAH | 2.5 | 17.9 | 3 | W | 2.9 | 162 qd | No | W dose> | No |
| 28 | TAH | 1.3 | 27.2 | 0 | W | 2.7 | 162 qd | No | W dose> | No |
| 29 | TAH | 4.2 | 29.0 | 3 | W | 2.3 | 325 qd | No | W dose< | No |
| 30 | HW | 0.5 | 66.5 | 0 | Argatroban | 1.8 | 325 qd | Dipyridamole added | No | No |
| 31 | HW | 2.1 | 55.2 | 1 | Argatroban | 1.5 | 325 qd | No | No | No |
| 32 | HMII | 1.4 | 70.4 | 2 | UFH | 1.2 | 162 qd | 81 qd | No | No |
| 33 | HW | 1.9 | 64.2 | 0 | W | 2.4 | 162 qd | No | No | No |
| 34 | HMII | −5.6 | 50.0 | 0 | W + UFH | 1.1 | 325 qd | No | W dose>, UFH discontinued | No |
| 35 | TAH | 0.0 | 53.0 | 0 | W | 2.0 | 81 qd | No | W dose> | No |
| 36 | TAH | 1.0 | 47.0 | 1 | W | 2.9 | 162 qd | No | W dose<, UFH added | OHT |
| 37 | TAH | −8.9 | 79.1 | 5 | UFH | 1.1 | 325 tid | No | No | No |
| 38 | TAH | 0.2 | 51.5 | 0 | W | 3.1 | 325 qd | No | W dose> | No |
| 39 | TAH | −0.6 | 73.3 | 1 | W | 2.9 | 325 bid | No | W dose< | No |
| 40 | TAH | −6.2 | 72.1 | 0 | W | 3.0 | 325 bid | No | W dose< | No |
| 41 | TAH | 2.8 | 48.5 | 1 | W | 3.2 | 325 tid | No | No | Expired |
| 42 | TAH | −0.2 | 61.4 | 2 | W | 3.1 | 325 bid | Dipyridamole added | No | GI bleed, rectal ulcers |
| 43 | TAH | 1.8 | 71.0 | 19 | UFH | 2.0 | 81 qd | 162 qd | W added | Venous thrombosis |
| 44 | TAH | −2.9 | 76.9 | 24 | W | 4.1 | 81 qd | Aspirin held | W held | No |
| 45 | TAH | 3.7 | 67.1 | 0 | W | 2.7 | 81 qd | No | No | No |
BiVAD, biventricular assisted device; W, warfarin; UFH, unfractionated heparin; +, additional anticoagulant added; >, dose increase; <, dose decrease; OHT, orthotopic heart transplant; GI, gastrointestinal. Interpretation guidelines for aspirin responsiveness: WBAAA cutoff <4 ohms; TPM cutoff for MAAA <50 mm. The range for a normocoagulable state (free from thrombotic events) for patients with HM II and HW devices should be maintained at a CI value ≤1.5, whereas patients on TAH devices should be maintained at a value ≤1.2.